Tarsons Products Ltd

AI
Tarsons Products Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Tarsons Products Ltd

₹ 360 15.22%
14 Aug - close price
tarsons.com BSE: 543399 NSE: TARSONS
About

Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals[1]

Key Points

India’s Leading Labware Company[1]
One of the leading Indian labware company engaged in designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop
equipment & instruments)

Website BSE NSE
  • Market Cap ₹ 1,917 Cr.
  • Current Price ₹ 360
  • High / Low ₹ 375 / 164
  • Stock P/E 162
  • Book Value ₹ 119
  • Dividend Yield 0.00 %
  • ROCE 4.56 %
  • ROE 2.38 %
  • Face Value ₹ 2.00
Edit ratios
Unsung hero
Rani Gaidinliu
She joined the resistance against British rule at 13 and led it after her cousin was executed. Arrested at 16, she spent years in prison without abandoning her cause.
Unsung hero
Pannalal Gupt
He participated in several movements, including the Quit India Movement, and joined hunger strikes. As an active volunteer, he organized events, inspected venues, hosted guests and connected people with leaders.

Pros

Cons

  • Stock is trading at 3.02 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • Company has a low return on equity of 4.68% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2021 Mar 2022 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
70.66 84.94 61.79 105.72 84.80 99.25 95.68 112.69 91.36 102.33 107.89 120.93 110.24
37.52 40.61 38.91 75.48 66.04 73.94 66.04 75.67 66.66 74.88 76.37 86.66 84.25
Operating Profit 33.14 44.33 22.88 30.24 18.76 25.31 29.64 37.02 24.70 27.45 31.52 34.27 25.99
OPM % 46.90% 52.19% 37.03% 28.60% 22.12% 25.50% 30.98% 32.85% 27.04% 26.82% 29.21% 28.34% 23.58%
2.46 2.58 3.24 3.38 2.91 8.43 0.85 3.78 3.34 5.80 7.07 6.83 5.98
Interest 1.37 0.45 2.51 4.25 4.32 4.84 5.03 5.20 5.07 5.18 6.05 6.25 6.27
Depreciation 5.35 7.24 10.06 12.33 11.03 14.03 17.41 20.03 19.94 22.48 25.04 29.08 27.02
Profit before tax 28.88 39.22 13.55 17.04 6.32 14.87 8.05 15.57 3.03 5.59 7.50 5.77 -1.32
Tax % 25.66% 24.89% 26.72% 39.50% 36.39% 30.80% 34.66% 34.49% 41.25% 40.61% 32.93% 27.56% 9.09%
21.47 29.46 9.93 10.32 4.02 10.29 5.26 10.20 1.78 3.32 5.04 4.18 -1.44
EPS in Rs 4.04 5.54 1.87 1.94 0.76 1.93 0.99 1.92 0.33 0.62 0.95 0.79 -0.27
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026 TTM
229 301 296 392 423 441
125 148 196 282 305 322
Operating Profit 103 153 100 111 118 119
OPM % 45% 51% 34% 28% 28% 27%
5 8 11 16 23 26
Interest 3 4 10 20 23 24
Depreciation 14 22 40 62 97 104
Profit before tax 92 135 61 45 22 18
Tax % 25% 25% 30% 34% 35%
69 101 43 30 14 11
EPS in Rs 3,583.25 18.92 8.01 5.60 2.69 2.09
Dividend Payout % 0% 0% 25% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 13%
3 Years: %
TTM: 11%
Compounded Profit Growth
10 Years: %
5 Years: -26%
3 Years: %
TTM: -57%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -11%
1 Year: 5%
Return on Equity
10 Years: %
5 Years: %
3 Years: 5%
Last Year: 2%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.19 11 11 11 11
Reserves 244 479 602 620 624
34 22 269 339 393
18 33 90 111 158
Total Liabilities 296 544 972 1,080 1,186
120 189 336 536 733
CWIP 22 32 267 233 159
Investments 0 0 0 0 0
153 323 369 311 295
Total Assets 296 544 972 1,080 1,186

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026
68 83 103 114 118
-64 -138 -285 -145 -130
-27 130 136 39 9
Net Cash Flow -23 75 -47 8 -3
Free Cash Flow 6 -48 -81 -37 -7
CFO/OP 89% 77% 121% 117% 107%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026
Debtor Days 75 79 96 74 74
Inventory Days 277 478 572 355 341
Days Payable 35 75 65 44 53
Cash Conversion Cycle 317 482 602 385 361
Working Capital Days 108 150 -1 38 -20
ROCE % 35% 7% 5%

Insights

In beta
Mar 2019 Mar 2020 Jun 2021 Mar 2023 Mar 2024 Mar 2025 Mar 2026
ODM Share of Export Revenue
% ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Product Mix - Consumables Revenue Share
% ・Standalone data
Product Mix - Reusables Revenue Share
% ・Standalone data
Domestic Distributors
count ・Standalone data
Number of Manufacturing Facilities
count ・Standalone data
Number of Product Segments
count ・Standalone data
Number of SKUs
count ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

30 Recently
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
47.31% 47.31% 47.31% 47.31% 47.31% 47.31% 47.31% 47.31% 47.31% 47.30% 47.30% 47.30%
7.85% 6.83% 8.16% 7.95% 8.04% 7.51% 9.53% 9.14% 5.82% 2.46% 0.87% 0.15%
3.15% 2.60% 0.17% 0.11% 0.21% 0.51% 0.30% 0.04% 0.08% 0.00% 0.19% 0.10%
41.68% 43.27% 44.36% 44.63% 44.45% 44.69% 42.89% 43.50% 46.79% 50.23% 51.65% 52.44%
No. of Shareholders 1,08,2361,07,5641,02,8661,05,33099,58696,92793,41790,89188,96687,33684,09383,453

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls